Saskia Ludwig1, Cathrin Theis2, Ben Brown3, Andreas Witthohn4, Wolfram Lux1, Andreas Goette5. 1. HGC GesundheitsConsult GmbH, Duesseldorf, Germany. 2. Robert-Bosch-Krankenhaus, Zentrum für Innere Medizin III Kardiologie, Auerbachstraße 110, 70376 Stuttgart, Germany. 3. Medtronic International Trading Sàrl, Route du Molliau 31, 1131 Tolochenaz, Switzerland. 4. Medtronic GmbH, Earl-Bakken-Platz 1, 40670 Meerbusch, Germany. 5. St. Vincenz Hospital Paderborn, Department of Cardiology and Intensive Care Medicine, Am Busdorf 2, 33098 Paderborn, Germany.
Abstract
AIM: Estimate incidence and costs of cardiac device infections (CDIs) in Germany. MATERIALS & METHODS: Patients had an implantable cardioverter defibrillator implanted over 2010-2013 and were followed to December 2014 using German health insurance claims data. A case-controlled analysis was performed using propensity score matching methods. RESULTS: Risk of CDI 12 months post-implant was 3.4% overall, either 2.9% for de novo procedures versus 4.4% for replacement procedures. Mean 3-year incremental expenditure per patient for patients with CDI compared with controls was €31,493 for de novo implant patients and €33,777 for replacement patients. Mean incremental expenditure was €59,419 per patient with a major infection. CONCLUSION: CDIs are highly expensive to manage, reinforcing the need for strategies to reduce their occurrence.
AIM: Estimate incidence and costs of cardiac device infections (CDIs) in Germany. MATERIALS & METHODS:Patients had an implantable cardioverter defibrillator implanted over 2010-2013 and were followed to December 2014 using German health insurance claims data. A case-controlled analysis was performed using propensity score matching methods. RESULTS: Risk of CDI 12 months post-implant was 3.4% overall, either 2.9% for de novo procedures versus 4.4% for replacement procedures. Mean 3-year incremental expenditure per patient for patients with CDI compared with controls was €31,493 for de novo implant patients and €33,777 for replacement patients. Mean incremental expenditure was €59,419 per patient with a major infection. CONCLUSION:CDIs are highly expensive to manage, reinforcing the need for strategies to reduce their occurrence.
Entities:
Keywords:
health economics; medical devices; outcomes research
Authors: Anna Polewczyk; Wojciech Jacheć; Maciej Polewczyk; Dorota Szczęśniak-Stańczyk; Andrzej Kutarski Journal: J Clin Med Date: 2022-07-06 Impact factor: 4.964
Authors: Fozia Zahir Ahmed; Catherine Fullwood; Mahvash Zaman; Ahmed Qamruddin; Colin Cunnington; Mamas A Mamas; Jonathan Sandoe; Manish Motwani; Amir Zaidi Journal: PLoS One Date: 2019-01-02 Impact factor: 3.240